With the continuous improvement of our understanding of mucin typing, the expansion of research samples and the increasing awareness of clinicians, we will get more evidence to support, continue to improve our clinical management of GIM and dysplasia patients, and ultimately improve the early detection rate of GC and reduce its mortality. Here, MUC5AC is linked to dysplasia.